2-溴甲基-4-噁唑羧酸甲酯 | 175551-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-溴甲基-4-噁唑羧酸甲酯
• 中文别名: 甲基2-(溴甲基)噁唑-4-甲酸酯
• 英文名称: methyl 2-(bromomethyl)oxazole-4-carboxylate
• 英文别名: 2-bromomethyl-4-carbomethoxyoxazole；Methyl 2-bromomethyl-4-oxazolecarboxylate；methyl 2-(bromomethyl)-1,3-oxazole-4-carboxylate
• CAS: 175551-77-6
• 化学式: C₆H₆BrNO₃
• 分子量: 220.023
• InChiKey: NXXLIQGNOSXXHB-UHFFFAOYSA-N

物化性质

• 熔点：
  49-51℃
• 沸点：
  245℃
• 密度：
  1.656
• 闪点：
  102℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-溴甲基-4-噁唑羧酸甲酯 在 lithium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以98%的产率得到(2-氯甲基)恶唑-甲酸甲酯
  参考文献：
  名称：

  Total synthesis of pristinamycin IIB

  摘要：

  An intramolecular Takai reaction of the iodoaldehyde 4a proceeded with a moderate efficiency to give the macrocyclic hydroxy compound Ib, identified to an authentic sample. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00499-7
• 作为产物：
  描述：

  t-butyl 2-(bromomethyl)oxazole-4-carboxylate 在 三氟乙酸 作用下， 生成 2-溴甲基-4-噁唑羧酸甲酯
  参考文献：
  名称：

  Total Synthesis of (−)-Virginiamycin M₂ Using Second-Generation Vinylogous Urethane Chemistry

  摘要：

  DOI：

  10.1021/ja954311z

文献信息

• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120015950A1

  公开（公告）日：2012-01-19

  Compound corresponding to general formula (I): in which R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy or NR 8 R 9 group; n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 or 2; A is a covalent bond or a C 1-8 -alkylene group; R 1 is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group, this group being optionally substituted; R 3 is a hydrogen or fluorine atom, a C 1-6 -alkyl group or a tritluoromethyl group; R 4 is a group selected from furanyl, pyrrolyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, tetrazolyl, oxazolone, oxazolidinone, isoxazolone, isoxazolidinone, isothiazolone, isothiazolidinone, imidazolone, imidazolidinone, pyrazolone, pyrazolidinone, oxadiazolone, thiadiazolone and triazolone, this group being optionally substituted; in the form of a base or of an addition salt with an acid. Therapeutic use.

  与一般式(I)对应的化合物：其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；n是等于1、2或3的整数，m是等于1或2的整数；A是共价键或C1-8-烷基烯基团；R1是苯基、吡啶基、吡啉基、嘧啶基、吡嗪基、三嗪基、萘基、喹啉基、异喹啉基、邻苯二嗪基、喹唑啉基、喹喜啉基、喹啉基、咔啉基或萘啉基团，该基团可选择性地被取代；R3是氢原子或氟原子、C1-6-烷基或三氟甲基基团；R4是从呋喃基、吡咯基、噻吩基、异噻唑基、噁唑基、异噁唑基、吡唑基、噁二唑基、噻二唑基、咪唑基、三唑基、四唑基、噁唑酮、噁唑烷酮、异噁唑酮、异噁唑烷酮、异噻唑酮、异噻唑烷酮、咪唑酮、咪唑烷酮、吡唑酮、吡唑烷酮、噁二唑酮、噻二唑酮和三唑酮中选择的基团，该基团可选择性地被取代；以盐酸形式或酸的加合盐形式存在。治疗用途。
• The Synthesis of Novel Disorazoles
  作者：Romy Schäckel、Bettina Hinkelmann、Florenz Sasse、Markus Kalesse

  DOI：10.1002/anie.200906450

  日期：2010.2.22

  Big little brother: The simplified disorazole analogue 1 exhibits its cytotoxic activity at low nanomolar concentrations and provides selectivities not observed for the parent natural product.

  大弟弟：简化的二异唑类类似物1在低纳摩尔浓度下表现出细胞毒活性，并提供母体天然产物未观察到的选择性。
• [EN] PYRIDAZINE DERIVATIVES AS RORc MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDAZINE UTILISÉS EN TANT QUE MODULATEURS DE RORC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016177760A1

  公开（公告）日：2016-11-10

  Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  公式I的化合物：或其药物盐，其中m，A，X，Y，Z，R1，R2，R3，R4和R5的定义如本文所述。还公开了制备这些化合物的方法，并使用这些化合物治疗炎症性疾病，如关节炎。
• [EN] PROCESS FOR PREPARING OXAZOLE DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES D'OXAZOLE
  申请人：GLAXO GROUP LTD

  公开号：WO2000053589A1

  公开（公告）日：2000-09-14

  A process for the preparation of a compound of formula (I) or a salt thereof or a carboxylic acid ester derivative thereof, wherein L represents a leaving group, which comprises (a) treating a compound of formula (II) wherein R represents COOH or a salt thereof or a derivative thereof and L and L1 represent leaving groups with a base such that L1 is eliminated and the oxazole ring is formed; and (b) if necessary converting the R moiety to COOH or a salt thereof or a carboxylic acid ester derivative thereof. A further aspect of this invention is the preparation of the potassium salt of a pyrrolidinyl derivative of compound of formula (I) and coupling of the said salt to an amine.

  一种制备式（I）化合物或其盐或羧酸酯衍生物的过程，其中L代表离去基团，包括（a）用碱处理式（II）化合物，其中R代表COOH或其盐或衍生物，L和L1代表离去基团，使L1被消除并形成噁唑环；以及（b）必要时将R基团转化为COOH或其盐或羧酸酯衍生物。本发明的另一方面是制备式（I）化合物的吡咯烷基衍生物的钾盐，并将该盐与胺偶联。